...
首页> 外文期刊>acta reumatologica portuguesa >Portuguese guidelines for the use of biological agents in rheumatoid arthritis - December 2007 update
【24h】

Portuguese guidelines for the use of biological agents in rheumatoid arthritis - December 2007 update

机译:

获取原文
获取原文并翻译 | 示例
           

摘要

abstract_textpThe authors present the revised version of the Portuguese Society of Rheumatology (SPR) guidelines for the treatment of rheumatoid arthritis (RA) with biological therapies. In these guidelines the criteria for introduction and maintenance of biological agents are discussed as well as the contraindications and procedures in case of non-responders. Biological treatment should be considered in RA patients with a disease activity score 28 (DAS 28) superior to 3.2 despite treatment with 20mg/week of methotrexate (MTX) for at least 3 months or, if such treatment is not possible, after 6 months of other conventional disease modifying drug or combination therapy. A DAS 28 score between 2.6 and 3.2 with a significant functional or radiological deterioration under treatment with conventional regimens could also constitute an indication for biological treatment. The follow-up should be performed each 3 months. The response criteria, at the end of the first 3 months of treatment, are a decrease of 0.6 in the DAS28 score. After 6 months of treatment response criteria is defined as follows: for those with an initial DAS28 score superior to 5.1, a reduction of the DAS28 score below 4 is required; for those with an initial DAS28 score inferior to 5.1, a decrease of the DAS28 score below 3.2 without a significant functional or radiological worsening is required. Non-responders, in accordance to the Rheumatologist's clinical opinion, should try a switch to other biological agent (tumour necrosis factor alpha antagonist, rituximab or abatacept)./p/abstract_text

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号